Edition:
United Kingdom

Qiagen NV (QGEN.N)

QGEN.N on New York Stock Exchange

34.80USD
21 Aug 2019
Change (% chg)

$0.63 (+1.84%)
Prev Close
$34.17
Open
$34.73
Day's High
$35.05
Day's Low
$34.60
Volume
159,406
Avg. Vol
304,765
52-wk High
$41.52
52-wk Low
$32.36

Latest Key Developments (Source: Significant Developments)

Qiagen Says Total Net Sales Rose 1% To $381.6 Mln In Q2 Of 2019
Wednesday, 24 Jul 2019 

July 24 (Reuters) - Qiagen NV ::QIAGEN REPORTS RESULTS FOR SECOND QUARTER OF 2019; UPDATES FULL-YEAR 2019 OUTLOOK DUE TO DECISION TO RESTRUCTURE CHINA NGS PARTNERSHIP.INTENDS TO RESTRUCTURE CURRENT FORMAT OF ITS NEXT-GENERATION SEQUENCING (NGS) PARTNERSHIP IN CHINA.TOTAL NET SALES ROSE 1% TO $381.6 MILLION IN Q2 OF 2019 FROM $377.2 MILLION IN Q2 OF 2018.SAYS NET INCOME WAS $44.7 MILLION IN Q2 OF 2019, OR $0.19 PER DILUTED SHARE COMPARED TO $36.8 MILLION, OR $0.16 PER SHARE.QTRLY ADJUSTED NET INCOME WAS $77.4 MILLION, OR $0.33 PER DILUTED SHARE.QTRLY OPERATING INCOME WAS $60.2 MILLION COMPARED TO $53.3 MILLION IN SAME QUARTER OF 2018.  Full Article

Qiagen Expands Collaboration With Diasorin On Lyme Disease Research
Wednesday, 5 Jun 2019 

June 5 (Reuters) - Qiagen ::QIAGEN AND DIASORIN COLLABORATE ON NOVEL QUANTIFERON-BASED TEST WITH BREAKTHROUGH POTENTIAL FOR EARLIER DETECTION OF LYME DISEASE.COMPANIES PLAN MULTI-SITE CLINICAL VALIDATIONS DURING 2020 LYME DISEASE SEASON.REGULATORY SUBMISSIONS EXPECTED AT END OF SAME YEAR IN UNITED STATES AND EUROPE.  Full Article

FDA Approves Novartis' Piqray, the First Pi3k Inhibitor For Breast Cancer
Friday, 24 May 2019 

May 24 (Reuters) - U.S. Food and Drug Administration::FDA APPROVES FIRST PI3K INHIBITOR FOR BREAST CANCER.FDA APPROVES FIRST PI3K INHIBITOR FOR BREAST CANCER.FDA- ALSO APPROVED COMPANION DIAGNOSTIC TEST, THERASCREEN PIK3CA RGQ PCR KIT, TO DETECT PIK3CA MUTATION IN A TISSUE AND/OR A LIQUID BIOPSY.  Full Article

Qiagen NV Says Liquid Biopsy-Based Precision Medicine Test To Guide Patient Selection For Inovio's Vgx-3100
Thursday, 16 May 2019 

May 16 (Reuters) - Qiagen NV ::QIAGEN AND INOVIO COLLABORATE TO DEVELOP COMPANION DIAGNOSTIC FOR NOVEL IMMUNOTHERAPY TARGETING PRECANCEROUS CERVICAL LESIONS.QIAGEN NV - LIQUID BIOPSY-BASED PRECISION MEDICINE TEST TO GUIDE PATIENT SELECTION FOR INOVIO'S VGX-3100.QIAGEN NV - INOVIO NOW AIMS TO MAKE REGULATORY SUBMISSIONS FOR VGX-3100 IN 2021.  Full Article

Qiagen Launches Companion Diagnostic Using FGFR Alterations To Help Guide Treatment Of Metastatic Urothelial Cancer
Friday, 12 Apr 2019 

April 12 (Reuters) - Qiagen NV ::QIAGEN LAUNCHES FIRST FDA-APPROVED COMPANION DIAGNOSTIC USING FGFR ALTERATIONS TO HELP GUIDE THE TREATMENT OF METASTATIC UROTHELIAL CANCER.QIAGEN NV - NOVEL THERASCREEN FGFR RGQ RT-PCR KIT WILL AID IN IDENTIFYING PATIENTS ELIGIBLE FOR TREATMENT WITH BALVERSA, DEVELOPED BY JANSSEN.  Full Article

FDA Says Granted Accelerated Approval To Janssen's Balversa
Friday, 12 Apr 2019 

April 12 (Reuters) - FDA::FDA APPROVES FIRST TARGETED THERAPY FOR METASTATIC BLADDER CANCER.FDA - GRANTED ACCELERATED APPROVAL TO BALVERSA (ERDAFITINIB).FDA - BALVERSA WAS ALSO GRANTED BREAKTHROUGH THERAPY DESIGNATION.FDA - ALSO APPROVED THERASCREEN FGFR RGQ RT-PCR KIT, DEVELOPED BY QIAGEN MANCHESTER FOR USE AS COMPANION DIAGNOSTIC WITH BALVERSA FOR INDICATION.  Full Article

Qiagen And LabCorp Launch Collaboration For Companion Diagnostics Access
Wednesday, 3 Apr 2019 

April 3 (Reuters) - Laboratory Corporation of America Holdings ::QIAGEN AND LABCORP LAUNCH COLLABORATION TO PROVIDE DAY-ONE ACCESS FOR PATIENTS TO INNOVATIVE COMPANION DIAGNOSTICS AT TIME OF DRUG APPROVALS.  Full Article

Qiagen And Tecan To Collaborate On Streamline Preanalytical Processing Of QuantiFERON-TB Gold Plus
Friday, 8 Mar 2019 

March 8 (Reuters) - Qiagen NV ::QIAGEN AND TECAN <<>> ANNOUNCE COLLABORATION TO STREAMLINE PREANALYTICAL PROCESSING OF QUANTIFERON-TB GOLD PLUS.  Full Article

Qiagen Partners With Ares Genetics, A Subsidiary Of Curetis N.V.
Monday, 18 Feb 2019 

Feb 18 (Reuters) - Qiagen NV ::QIAGEN PARTNERS WITH ARES GENETICS TO ADVANCE GLOBAL FIGHT AGAINST ANTIBIOTIC-RESISTANT PATHOGENS.QIAGEN NV - BROAD AGREEMENT WITH ARES GENETICS, A SUBSIDIARY OF CURETIS N.V..QIAGEN NV - ACQUIRED AN EXCLUSIVE LICENSE TO LEVERAGE ARES GENETICS' PROPRIETARY ANTIMICROBIAL RESISTANCE DATABASE.QIAGEN NV - OBTAINED NON-EXCLUSIVE WORLDWIDE LICENSE TO DEVELOP, COMMERCIALIZE MOLECULAR RESEARCH ASSAYS USING ARESDB CONTENT.QIAGEN NV - FINANCIAL DETAILS OF PARTNERSHIP WERE NOT DISCLOSED.  Full Article

Qiagen Reports Q4 EPS Of $0.26
Monday, 4 Feb 2019 

Feb 4 (Reuters) - Qiagen NV ::QTRLY NET SALES OF $403.2 MILLION.QTRLY EPS OF $0.26.QTRLY ADJUSTED EPS $0.40.QIAGEN SETS 2019 OUTLOOK FOR FURTHER GROWTH IN NET SALES AND ADJUSTED EPS.SAYS IN 2019 NET SALES ARE EXPECTED TO GROW ABOUT 7-8% CER.Q4 REVENUE VIEW $408.6 MILLION -- REFINITIV IBES DATA.Q4 EARNINGS PER SHARE VIEW $0.40 -- REFINITIV IBES DATA.SAYS EXPECTS ADJUSTED DILUTED EPS OF ABOUT $1.45-1.47 CER PER SHARE FOR FULL-YEAR 2019.FY2018 REVENUE VIEW $1.51 BILLION -- REFINITIV IBES DATA.FY2018 EARNINGS PER SHARE VIEW $1.35 -- REFINITIV IBES DATA.QIAGEN - CURRENCY MOVEMENTS AGAINST THE U.S. DOLLAR ARE EXPECTED TO HAVE AN ADVERSE IMPACT ON RESULTS OF ABOUT ONE PERCENTAGE POINT ON FULL-YEAR 2019 NET SALES.QIAGEN - CURRENCY MOVEMENTS AGAINST THE U.S. DOLLAR ARE EXPECTED TO HAVE AN ADVERSE IMPACT OF ABOUT $0.01 ON ADJUSTED DILUTED EPS IN FY19.SAYS FOR THE FIRST QUARTER OF 2019, NET SALES ARE EXPECTED TO GROW ABOUT 5-6% CER.SAYS FOR Q1 2019 ADJUSTED DILUTED EPS IS EXPECTED TO BE ABOUT $0.26-0.27 CER.SAYS NET SALES GREW 2% TO $403.2 MILLION IN THE FOURTH QUARTER OF 2018 OVER THE YEAR-AGO PERIOD.  Full Article

German stocks - Factors to watch on July 25

BERLIN/FRANKFURT, July 25 The following are some of the factors that may move German stocks on Thursday: